| Autor: |
Elmahallawy, N. M. N., Elsheikh, M. M., Mahmoud, D. A., Ibrahim, M. A. |
| Předmět: |
|
| Zdroj: |
QJM: An International Journal of Medicine; 2020 Supplement, Vol. 113, pi143-i143, 1/3p |
| Abstrakt: |
Background: Over the past few years, prescriptions of antipsychotic medications have risen significantly. In particular, there is increasing use of second- and third-generation antipsychotic agents. However, numerous studies have shown clinically relevant adverse effects (such as weight gain, metabolic disorders, prolactin changes, and extrapyramidal symptoms [EPS]) with these therapeutic agents. The objective of this article is to provide a comparative review of the safety data available for antipsychotic drug use. Methods: review the available literatures and case studies done on the neuro-endocrinal effects of the antipsychotics for the past 20 years from the following database: libraries of faculties of medicine of various Egyptian universities and database of various journals of psychiatry and through Pubmed and Scopus search engines. Limitations: Absence of Arabic studies. Shortage of modern references. Conclusions: Atypical antipsychotics are thought to be safer than typical antipsychotics, so they are the first-line of treatment at first-episode of psychosis, at least in the short-term. But, atypical antipsychotics still have severe neuro-endocrinal side effects. Each drug should be considered according to their suited to the patient. To avoid the side effects, choose the suitable antipsychotic drug, use the lowest efficatious dose; the minimum dose and duration of treatment, have good communication with the patients about the side effects to treat them immediately when they appear and to stop the medication. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
